Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors

NCT05639933 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

152

Enrollment

OTHER

Sponsor class

Conditions

Acneiform Eruption Due to Chemical
Xerosis Cutis
Paronychia

Interventions

DRUG: HT-001 2% Topical Gel
DRUG: HT-001 1% Topical Gel
DRUG: HT-001 0.5% Topical Gel
DRUG: HT-001 Placebo

Sponsor

Hoth Therapeutics, Inc.

Collaborators

[object Object]